Market Cap 484.38M
Revenue (ttm) 10.12M
Net Income (ttm) -220.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,180.43%
Debt to Equity Ratio 0.00
Volume 1,870,392
Avg Vol 2,156,896
Day's Range N/A - N/A
Shares Out 266.14M
Stochastic %K 70%
Beta 1.98
Analysts Strong Sell
Price Target $8.99

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL;...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3829 6230
Address:
The Mediaworks, 191 Wood Lane White City, London, United Kingdom
TradeSun
TradeSun Feb. 26 at 8:24 PM
$AUTL Pretty good job! It seems she wants more... I recommend taking a look at the 2y- chart.
0 · Reply
XX1XX
XX1XX Feb. 26 at 6:23 PM
$AUTL expected pullback after hitting +1 on standard deviation line (1 year) yesterday. If it starts to break above this and continues to rise, you know something is up otherwise its just standard algo trading going into earnings.
1 · Reply
Fadoman
Fadoman Feb. 26 at 5:03 PM
$AUTL on the 30 min the momentum is there ready to go up again... I don't know how much, however.
1 · Reply
JanetBSmellin
JanetBSmellin Feb. 26 at 4:42 PM
$AUTL I’m in. Like the science and the cash position. 😎👍🏼
1 · Reply
Roadto1mio
Roadto1mio Feb. 26 at 3:37 PM
$AUTL hopefully the last dip before heading to the PT of 9$
0 · Reply
LatteLove
LatteLove Feb. 26 at 2:22 PM
$AUTL $1.73 gap fill?
0 · Reply
Roadto1mio
Roadto1mio Feb. 26 at 4:48 AM
$AUTL and back to 1.86, let’s keep going 🗣️
0 · Reply
Michael_garic
Michael_garic Feb. 26 at 2:06 AM
$AUTL What to look for on Thursday....opinion The shorts used almost half the daily volume on Wednesday (approx. 700k shares) just to force a $0.06 drop, it reveals a massive weakness: they are out of "cheap" ammunition. When short sellers have to exert that much energy for such a tiny result, it usually leads to one of two scenarios. Short sellers cannot sell the same shares twice. Since they already "spent" their firepower on Wednesday to push the price to $1.76, they need the price to stay down so they can cover profitably. If buyers (Longs) see that the shorts failed to break the $1.70 support despite massive effort, they will likely "buy the dip. Without another 700k shares of selling pressure to hold it down, the stock could easily "snap back" and reclaim the $1.82 - $1.85 range quickly. Most of the shorts who entered on Wednesday are currently "underwater" or barely breaking even.
3 · Reply
Michael_garic
Michael_garic Feb. 26 at 1:34 AM
$AUTL shorts in control capping the price.... for now On Wednesday, February 25, 2026, the short volume for AUTL was approximately 49.8% of the total off-exchange (FINRA) trading volume. Feb 25:Total FINRA Volume: ~1,412,000 shares. FINRA Short Volume: ~703,200 shares or 49.8%. Nearly half of the day's off-exchange volume was attributed to short sales. In the biotech sector, a 50% short volume is common, but it indicates that "bears" were very active in capping any potential upward momentum on Wednesday. When short volume is this high, it usually means that for every buyer trying to push the price up, there is a short seller providing "counter-liquidity," which can make it difficult for the stock to sustain a rally without a major catalyst. A portion of "short volume" often comes from market makers who sell shares they don't yet have in order to fulfill buy orders (keeping the market fluid). However, a consistent level near 50% still points to a heavily contested price zone.
0 · Reply
LatteLove
LatteLove Feb. 25 at 11:18 PM
$AUTL this trap keeps going. Looking for support here.
0 · Reply
Latest News on AUTL
Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?

Nov 25, 2025, 12:37 PM EST - 3 months ago

Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?


Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 3:11 PM EST - 3 months ago

Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript


Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:37 PM EDT - 7 months ago

Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript


Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

May 11, 2025, 4:22 AM EDT - 10 months ago

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript


TradeSun
TradeSun Feb. 26 at 8:24 PM
$AUTL Pretty good job! It seems she wants more... I recommend taking a look at the 2y- chart.
0 · Reply
XX1XX
XX1XX Feb. 26 at 6:23 PM
$AUTL expected pullback after hitting +1 on standard deviation line (1 year) yesterday. If it starts to break above this and continues to rise, you know something is up otherwise its just standard algo trading going into earnings.
1 · Reply
Fadoman
Fadoman Feb. 26 at 5:03 PM
$AUTL on the 30 min the momentum is there ready to go up again... I don't know how much, however.
1 · Reply
JanetBSmellin
JanetBSmellin Feb. 26 at 4:42 PM
$AUTL I’m in. Like the science and the cash position. 😎👍🏼
1 · Reply
Roadto1mio
Roadto1mio Feb. 26 at 3:37 PM
$AUTL hopefully the last dip before heading to the PT of 9$
0 · Reply
LatteLove
LatteLove Feb. 26 at 2:22 PM
$AUTL $1.73 gap fill?
0 · Reply
Roadto1mio
Roadto1mio Feb. 26 at 4:48 AM
$AUTL and back to 1.86, let’s keep going 🗣️
0 · Reply
Michael_garic
Michael_garic Feb. 26 at 2:06 AM
$AUTL What to look for on Thursday....opinion The shorts used almost half the daily volume on Wednesday (approx. 700k shares) just to force a $0.06 drop, it reveals a massive weakness: they are out of "cheap" ammunition. When short sellers have to exert that much energy for such a tiny result, it usually leads to one of two scenarios. Short sellers cannot sell the same shares twice. Since they already "spent" their firepower on Wednesday to push the price to $1.76, they need the price to stay down so they can cover profitably. If buyers (Longs) see that the shorts failed to break the $1.70 support despite massive effort, they will likely "buy the dip. Without another 700k shares of selling pressure to hold it down, the stock could easily "snap back" and reclaim the $1.82 - $1.85 range quickly. Most of the shorts who entered on Wednesday are currently "underwater" or barely breaking even.
3 · Reply
Michael_garic
Michael_garic Feb. 26 at 1:34 AM
$AUTL shorts in control capping the price.... for now On Wednesday, February 25, 2026, the short volume for AUTL was approximately 49.8% of the total off-exchange (FINRA) trading volume. Feb 25:Total FINRA Volume: ~1,412,000 shares. FINRA Short Volume: ~703,200 shares or 49.8%. Nearly half of the day's off-exchange volume was attributed to short sales. In the biotech sector, a 50% short volume is common, but it indicates that "bears" were very active in capping any potential upward momentum on Wednesday. When short volume is this high, it usually means that for every buyer trying to push the price up, there is a short seller providing "counter-liquidity," which can make it difficult for the stock to sustain a rally without a major catalyst. A portion of "short volume" often comes from market makers who sell shares they don't yet have in order to fulfill buy orders (keeping the market fluid). However, a consistent level near 50% still points to a heavily contested price zone.
0 · Reply
LatteLove
LatteLove Feb. 25 at 11:18 PM
$AUTL this trap keeps going. Looking for support here.
0 · Reply
BRLondon
BRLondon Feb. 25 at 10:06 PM
$AUTL I'm not trading for pennies.
0 · Reply
TradeSun
TradeSun Feb. 25 at 9:36 PM
$ALT $AUTL Nice double beat for NVDA. Good for tomorrows market!👍 A domani!☀️
1 · Reply
TradeSun
TradeSun Feb. 25 at 9:03 PM
$AUTL Nice consolidation!
0 · Reply
Roadto1mio
Roadto1mio Feb. 25 at 8:36 PM
$AUTL nah I‘m not getting shaked out, he’ll nah
1 · Reply
TricksterT
TricksterT Feb. 25 at 8:33 PM
$AUTL stopped out as I wasn’t willing to ride the down trend for a 3rd time. I’ll be back though! GL
3 · Reply
TradeSun
TradeSun Feb. 25 at 8:17 PM
$AUTL Support 1.78 seems to be strong👍🏻
0 · Reply
bangguman
bangguman Feb. 25 at 8:08 PM
$AUTL As expected, it doesn’t look like it will break through the weekly Bollinger Band. It’s likely to enter another downtrend.
0 · Reply
diggs24
diggs24 Feb. 25 at 7:42 PM
0 · Reply
TradeSun
TradeSun Feb. 25 at 7:30 PM
$AUTL If the blue line works, it would be a perfect and strong consolidation.
0 · Reply
gandolf63
gandolf63 Feb. 25 at 7:25 PM
$AUTL hoping we don’t pull back to the $1.40’s again
0 · Reply
TradeSun
TradeSun Feb. 25 at 6:26 PM
$AUTL Wow! Thx👍 Autolus is a UK-based CAR-T cell therapy company, spun out of University College London (UCL). Its scientific foundation is unusually strong: the company was founded by Dr. Martin Pule, who simultaneously leads UCL’s CAR-T program — the largest in Europe. The Science The key differentiator is Autolus’ proprietary “Fast Off-Rate” CAR-T design, which was specifically engineered to solve two major weaknesses of older CAR-T therapies: dangerous immune overreactions (Cytokine Release Syndrome / CRS) and poor long-term persistence of T-cells in the body. The results speak for themselves — in the pivotal FELIX trial, only 2.4% of patients experienced severe CRS, compared to roughly 24% with competing therapies. Clinical Results 1/2
2 · Reply
Deivittt
Deivittt Feb. 25 at 4:22 PM
$AUTL I think the problems with short positions haven't even started yet. It's not a bad idea to start covering those positions. We have one of the best scientific and management teams in the world at the helm. 🧭🚢
0 · Reply